

NCI's Clinical Trials Cooperative Groups National Meetings Report

Summer 2009

In This Issue

AACR, ASCO, ASCO GI Cancers Symposium, ASCO GU Cancers Symposium, International Symposium on Childhood, Adolescent & Young Adult Non-Hodgkin's Lymphoma, SGO, The Society for Clinical Trials, The Society of Surgical Oncology

Cooperative Group Abstracts:

- [Breast Cancer](#)
- [CNS Cancer](#)
- [Gastrointestinal Cancer](#)
- [Genitourinary Cancer](#)
- [Gynecologic Cancer](#)
- [Head and Neck Cancer](#)
- [Leukemia](#)
- [Myelodysplasia, and Transplantation](#)
- [Lung Cancer](#)
- [Lymphoma and Plasma Cell Disorders](#)
- [Sarcoma/Bone and Soft Tissue Cancers](#)
- [Other Cancer](#)

NCI/CTEP Abstracts & Activities:

[DCTD/DCP Abstracts](#)

Significant Publications of Interest:

[RECIST Version 1.1](#)



The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in July (post AMI, AACR, ACRIN, ASCO and SNM) and in January (post ASCO Breast Symposium, ASH, ASTRO, ISOQOL, RSNA, SABCS, SGO and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

ANBL0032: This phase 3 study evaluated the addition of the anti-GD2 monoclonal antibody ch14.18 plus cytokines (GM-CSF and IL2) to standard therapy of 13-cis-retinoic acid (RA) for children with high-risk neuroblastoma following intensive induction and consolidation therapy. The ANBL0032 study demonstrated that ch14.18 plus cytokines significantly improved event-free survival for high-risk neuroblastoma patients, thereby establishing a new standard of care for this patient population after completion of intensive conduction and consolidation therapy.

NSABP-C-08: This is the first phase 3 adjuvant trial evaluating an anti-angiogenesis agent in combination with standard chemotherapy for patients with early stage, resectable colon cancer (stage II and stage III). Although bevacizumab in combination with chemotherapy is considered a standard, first-line treatment for patients with metastatic colorectal cancer based on improvements in overall survival demonstrated in randomized, phase 3 trials in that clinical setting, bevacizumab did not improve 3-year disease-free survival in patients with early stage disease.



Cancer Trials Support Unit
A SERVICE OF THE NATIONAL CANCER INSTITUTE
Linking practice to progress



CureSearch
Children's Oncology Group

ACOSOG

NSABP[®]
National Surgical Adjuvant Breast and Bowel Project



Eastern Cooperative Oncology Group

RTOG[®]
RADIATION THERAPY ONCOLOGY GROUP



Southwest Oncology Group
A National Clinical Research Group



National Cancer Institute of Canada
Institut national du cancer du Canada
Clinical Trials Group
Groupe des essais cliniques



Cooperative Group Abstracts

Breast Cancer

ACOSOG

Wilke LG, McCall LM, Leitch AM, Ballman KV, Hunt KK, Giuliano AE: Adherence to the National Quality Forum (NQF) Measures in a Multi-Institutional Breast Cancer Clinical Trial. The Society of Surgical Oncology, Phoenix, Arizona, Mar, 2009. Abst. P72.

http://sso2009.abstractcentral.com/viewer?TAG_ACTION=VIEW_PROOF&ABSTRACT_ID=546871&SHOW_COMMENT=FALSE&NEXT_PAGE=PROOF_POP&SHOW_RECEIPT=FALSE&BLIND_OVERRIDE=TRUE&VIEWER_SHOW_PRINT=Y

Protocol(s): ACOSOG-Z0010

ACRIN

Hylton N, Blume J, Gatsonis C, Gomez R, Bernreuter W, Pisano E, Rosen M, Marques H, Esserman L, Schnall M: MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN 6657/CALGB 150007. J Clin Oncol 2009; 27(15S):Abst. 529.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/529>

Protocol(s): ACRIN-6657

CALGB

DeMichele A, Dunn L, Gimotty P, Livasy C, Perou C, Carey L, Esserman L: Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657). J Clin Oncol 2009; 27(15S):Abst. 11091.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/11091>

Protocol(s): CALGB-150007

Esserman LJ, Perou C, Cheang M, DeMichele A, Carey L, van 't Veer LJ, Gray J, Petricoin E, Conway K, Hylton N, Berry D: Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). J Clin Oncol 2009; 27(15S):Abst. LBA515.

<http://meeting.ascopubs.org/cgi/content/abstract/27/18S/LBA515>

Protocol(s): CALGB-150007

Lin C, Moore D, DeMichele A, Ollila D, Montgomery L, Liu M, Krontiras H, Gomez R, Esserman L: Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening. J Clin Oncol 2009; 27(15S):Abst. 1503.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/1503>

Protocol(s): CALGB-150007

Liotta L, Pierobon M, Wulfkuhle J, Laird J, Livasy C, Espina V, Esserman L, Petricoin E: Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes. J Clin Oncol 2009; 27(15S):Abst. 11014.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/11014>

Protocol(s): CALGB-150007

Mandelblatt J, Sheppard V, Hurria A, Kimmick G, Isaacs C, Taylor K, Luta G, Noone A, Kornblith A, Barry W: Patient preference as a determinant of breast cancer adjuvant chemotherapy use in older women: CALGB #369901. J Clin Oncol 2009; 27(15S):Abst. 9544.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/9544>

Protocol(s): CALGB-369901

van 't Veer LJ, Esserman LJ, Linn S, Rutgers E, Knauer M, Retel V, Davis SE, Lin C: Evaluation of the effect of screening on the detection of good and poor prognosis breast cancers. J Clin Oncol 2009; 27(15S):Abst. 1525.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/1525>

Protocol(s): CALGB-150007

Wulfkuhle J, Pierobon M, Laird J, Espina V, Liotta IL, Esserman L, Petricoin E: Discovery of a new phospho-HER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping. J Clin Oncol 2009; 27(15S):Abst. 11009.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/11009>

Protocol(s): CALGB-150007

ECOG

Carlson RW, O'Neill A, Vidaurre T, Gomez Moreno HL, Badve SS, Sledge GW: Randomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancer. J Clin Oncol 2009; 27(15S):Abst. 1013.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/1013>

Protocol(s): E4101

Sparano JA, Goldstein LJ, Childs BH, Shak S, Badve SS, Baehner FL, Davidson NE, Sledge GW, Gray RJ: Genotypic characterization of phenotypically defined triple-negative breast cancer. J Clin Oncol 2009; 27(15S):Abst. 500.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/500>

Protocol(s): E2197

NCCTG

Apsey H, Roy V, Pockaj B, Northfelt D, Sticca R, Nikceovich DA, Mattar B, Fitch T, Perez EA: Surgical practice patterns following NCCTG N0338 "Phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer". J Clin Oncol 2009; 27(15S):Abst. 623.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/623>

Protocol(s): N0338

Moreno-Aspitia A, Hillman DW, Dueck AC, Carney WP, Lingle WL, Tenner KS, Lafky JM, Reinholz MM, Kutteh LA, Perez EA: Baseline and recurrence levels of soluble HER2 (sHER2) in early-stage HER2-neu positive breast cancer (HER2+BC) from the NCCTG adjuvant Intergroup trial N9831. J Clin Oncol 2009; 27(15S):Abst. 539.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/539>

Protocol(s): N9831

Reinholz MM, Kitzmann KA, Hobday TJ, Northfelt DW, LaPlant B, Allred JB, Dueck AC, Stella PJ, Lingle WL, Perez EA: Cytokeratin-19 (CK19) and mammaglobin (MGB1) gene expression in circulating tumor cells (CTCs) from metastatic breast cancer patients enrolled in the NCCTG trials, N0436 and N0437. *J Clin Oncol* 2009; 27(15S):Abst. 11095.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/11095>

Protocol(s): N0437, N0436

Sukov WR, Miller DV, Dueck AC, Tenner KS, Jenkins RB, Kaufman PA, Davidson NE, Dakhil SR, Martino S, Roy V, Perez EA: Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. *J Clin Oncol* 2009; 27(15S):Abst. 520.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/520>

Protocol(s): N9831

Tan W, Allred J, Salim M, Flynn P, Kugler JW, Stella PJ, Wiesenfeld M, Bernath AM, Fitch TR, Perez EA: N0337: Phase II study of capecitabine in combination with vinorelbine and trastuzumab for the first or second treatment of HER2+ metastatic breast cancer. *J Clin Oncol* 2009; 27(15S):Abst. 1020.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/1020>

Protocol(s): N0337

NSABP

Yang SX, Costantino JP, Nguyen D, Jeong J, Mamounas EP, Wolmark N, Kim C, Kidwell K, Paik S, Swain SM: Correlation of levels of Akt phosphorylation at Ser473 with benefit from paclitaxel chemotherapy in NSABP B-28 patients with node-positive breast cancer. *J Clin Oncol* 2009; 27(15S):Abst. 537.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/537>

Protocol(s): NSABP-B-28

CNS Cancer

CALGB

Khalil M, Wulfschuhle J, Fillmore H, Deng J, Liotta L, Petricoin E, Watson J, Broaddus W: Functional pathway mapping of human glioblastoma multiforme and brain metastases for patient tailored therapy. *J Clin Oncol* 2009; 27(15S):Abst. 2076.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/2076>

Protocol(s): CALGB-150007

RTOG

Aldape K, Jones G, Wang M, Hegi M, Janzer R, Stupp R, Mehta M, Gilbert M: MGMT methylation testing in RTOG 0525: A phase III trial of newly diagnosed glioblastoma. *J Clin Oncol* 2009; 27(15S):Abst. 2051.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/2051>

Protocol(s): RTOG-0525

Gilbert M, Wang M, Aldape K, Sorensen A, Walker E, Regine W, Glass J, Lassman A, Mehta M: RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). *J Clin Oncol* 2009; 27(15S):Abst. 2011.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/2011>

Protocol(s): RTOG-0625

Wang M, Cairncross G, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Souhami L, Laperriere N, Mehta M, Curran W: Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation therapy oncology group trial 9402. *J Clin Oncol* 2009; 27(15S):Abst. e20519.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e20519>

Protocol(s): INT-0149

SWOG

Swinnen LJ, Rankin C, Rushing EJ, Laura HF, Damek DM, Barger GR: Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811). *J Clin Oncol* 2009; 27(15S):Abst. 2063.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/2063>

Protocol(s): S9811

Gastrointestinal Cancer

ACRIN

Siewert B, Gareen I, Vanness D, Herman B, Johnson CD, Gatsonis C: ACRIN 6664: Patient acceptance and preference of CT colonography compared to optical colonoscopy for colon cancer screening. *J Clin Oncol* 2009; 27(15S):Abst. 4034.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4034>

Protocol(s): ACRIN-6664

CALGB

Bertagnolli MM, Niedzwiecki D, Hall M, Jewell SD, Mayer RJ, Goldberg RM, Colacchio TA, Warren RS, Redston M: Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581. *J Clin Oncol* 2009; 27(15S):Abst. 4012.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4012>

Protocol(s): CR-95-036

Fuchs C, Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Bertagnolli MM: KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. *J Clin Oncol* 2009; 27(15S):Abst. 4037.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4037>

Protocol(s): C89803

Innocenti F, Owzar K, Cox N, Evans P, Kubo M, Hollis D, Mushiroda T, Kindler HL, Nakamura Y, Ratain MJ: Heritable interleukin-17F (IL17F) gene variation and overall survival (OS) in pancreatic cancer patients (pts): Results from a genome-wide association study (GWAS) in CALGB 80303. J Clin Oncol 2009; 27(15S):Abst. 4531.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4531>

Protocol(s): CALGB-80303

Meyerhardt JA, Jackson McCleary N, Niedzwiecki D, Hollis D, Venook A, Mayer R, Goldberg R: Impact of age and comorbidities on treatment effect, tolerance, and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203. J Clin Oncol 2009; 27(15S):Abst. 4038.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4038>

Protocol(s): CALGB-80203

Meyers MO, Hollis DR, Mayer RJ, Goldberg RM, Benson III AB, Cummings B, Gunderson LL, Martenson JA, Macdonald JS, O'Connell M, Tepper JE: Use of the ratio of metastatic to examined lymph nodes to predict local recurrence in rectal cancer: Analysis of data from intergroup trial 0114. ASCO Gastrointestinal Cancers Symposium, San Francisco, California, Jan, 2009. Abst. 384.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=63&abstractID=10558

Protocol(s): INT-0114

ECOG

Luketich JD, Pennathur A, Catalano P, Swanson S, DeHoyos A, Maddaus M, Nguyen N, Jobe B, Benson AB, Fernando HC: Results of a phase II multicenter study of minimally invasive esophagectomy (Eastern Cooperative Oncology Group Study E2202). J Clin Oncol 2009; 27(15S):Abst. 4516.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4516>

Protocol(s): E2202

Yoon HH, Powell M, Gibson MK, Montgomery EA, Michael H, Catalano P, Liu G, Skaar T, Dolan E, Wu X, Forastiere AA, Benson AB, Kleinberg LR, Murphy K: Outcome prediction based on genetic polymorphisms (GPs) in epidermal growth factor (EGF) pathway in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. 1621.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={D48677CC-C7C2-4AD7-91A8-519359E5BF50}&SKey={5D0D0FA6-C791-4603-AF48-17763BE631AF}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): E1201

Yoon HH, Powell M, Murphy K, Montgomery EA, Hafez MJ, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK: Outcome prediction based on single nucleotide polymorphisms (SNPs) in DNA repair paths in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol 2009; 27(15S):Abst. 4530.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4530>

Protocol(s): E1201

NCCTG

Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Patiyil S, Thome S, Gill S, Sargent D: Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators. J Clin Oncol 2009; 27(15S):Abst. e15031.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e15031>

Protocol(s): Multiple Trials

Burzykowski T, Bang Y: Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-analysis. J Clin Oncol 2009; 27(15S):Abst. 4517.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4517>

Protocol(s): Multiple Trials

Buyse ME, Pignon J: Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy and prognostic factors in gastric cancer. J Clin Oncol 2009; 27(15S):Abst. 4539.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4539>

Protocol(s): Multiple Trials

French AJ, Sinicrope F, Foster NR, Thibodeau SN, Sargent DJ, O'Connell MJ: Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers. J Clin Oncol 2009; 27(15S):Abst. 11093.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/11093>

Protocol(s): Multiple Trials

Gill S, Loprinzi C, Kennecke H, Grothey A, Nelson G, Woods R, Speers C, Alberts S, Bardia A, Sargent D: Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!). J Clin Oncol 2009; 27(15S):Abst. 4044.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4044>

Protocol(s): Multiple Trials

Jackson McCleary NA, Meyerhardt J, Green E, Yothers G, de Gramont A, Van Cutsem E, O'Connell M, Twelves C, Saltz L, Sargent D: Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. J Clin Oncol 2009; 27(15S):Abst. 4010.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4010>

Protocol(s): Multiple Trials

Pozzo C, Ohashi Y: Meta-analyses of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/recurrent gastric cancer. J Clin Oncol 2009; 27(15S):Abst. 4550.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4550>

Protocol(s): Multiple Trials

Sinicrope F, Foster NR, Sargent DJ, Alberts SR, O'Connell MJ: Prognostic impact of body mass index upon cancer recurrence and survival in stage III colon cancer patients from adjuvant chemotherapy trials. J Clin Oncol 2009; 27(15S):Abst. 11088.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/11088>

Protocol(s): Multiple Trials

Tsikitis VL, Malireddy K, Green EA, Christensen B, Whelan R, Hyder J, Lauter D, Marcello P, Larach S, Sargent D, Nelson H: Postoperative surveillance recommendations for early-stage colon cancer based on results from the clinical outcomes of surgical therapy trial. *J Clin Oncol* 2009; 27(15S):Abst. 4013.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4013>

Protocol(s): NCCTG-93-46-51

NSABP

Jackson-McCleary NA, Meyerhardt J, Green E, Yothers G, de Gramont A, Van Cutsem E, O'Connell M, Twelves C, Saltz L, Sargent D: Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. *J Clin Oncol* 2009; 27(15S):Abst. 4010.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4010>

Protocol(s): NSABP-C-07

Kerr D, Gray R, Quirke P, Watson D, Yothers G, Lavery IC, Lee M, O'Connell MJ, Wolmark N, Shak S: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. *J Clin Oncol* 2009; 27(15S):Abst. 4000.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4000>

Protocol(s): NSABP-C-01, NSABP-C-02, NSABP-C-04, NSABP-C-06

Kunitake H, Zheng P, Yothers G, Land SR, Fehrenbacher L, Giguere JK, Wickerham DL, Ganz PA, Ko CY: Routine preventive care and cancer surveillance in long-term survivors (LTS) of colorectal cancer: Results from NSABP Protocol LTS-01. *J Clin Oncol* 2009; 27(15S):Abst. 6500.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6500>

Protocol(s): NSABP-LTS-01

Sargent DJ, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Shi Q, Buyse M, de Gramont A: Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803. *J Clin Oncol* 2009; 27(15S):Abst. 4011.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4011>

Protocol(s): NSABP-C-06, NSABP-C-07, C89803

Wilkinson NW, Yothers G, Lopa SH, Costantino J, Petrelli N, Wolmark N: Long-term results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: Pooled analysis of NSABP adjuvant trials C-01 through C-05. *The Society of Surgical Oncology*, Phoenix, Arizona, Mar, 2009. Abst. P11.

Protocol(s): NSABP-C-01, NSABP-C-02, NSABP-C-03, NSABP-C-04, NSABP-C-05

Wolmark N, Yothers G, O'Connell MJ, Sharif S, Atkins JN, Seay TE, Fehrenbacher L, O'Reilly S, Allegra CJ: A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. *J Clin Oncol* 2009; 27(15S):Abst. LBA4.

<http://meeting.ascopubs.org/cgi/content/abstract/27/18S/LBA4>

Protocol(s): NSABP-C-08

RTOG

Rink L, Skorobogatko Y, Kossenkov A, Belinsky M, Pajak T, von Mehren M, Ochs M, Eisenberg B, Godwin A: Correlation of gastrointestinal stromal tumor (GIST) gene expression signatures and response to imatinib mesylate in the Radiation Therapy Oncology Group phase II clinical trial S-0132. *J Clin Oncol* 2009; 27(15S):Abst. 10533.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10533>

Protocol(s): RTOG-0132

Van den Abbeele A, Gatsonis C, de Vries D, Melenevsky Y, Szot Barnes A, Yap J, Godwin A, Blevins M, Eisenberg B, Siegel B: ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate (IM) for primary and recurrent operable malignant GIST: Imaging findings and correlation with genotype and GLUT4 expression. *J Clin Oncol* 2009; 27(15S):Abst. 10552.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10552>

Protocol(s): RTOG-0132

Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot Barnes A, Yap JT, Godwin AK, Blevins M, Eisenberg B, Siegel BA: ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate (IM) for primary and recurrent operable malignant GIST: Imaging findings and correlation with genotype and GLUT4 expression. *J Clin Oncol* 2009; 27(15S):Abst. 10552.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10552>

Protocol(s): RTOG-0132

SWOG

Leichman L, Goldman BH, Benedetti JK, Billingsley KG, Thomas CR, Iqbal S, Lenz H, Blanke C, Gold PJ, Corless CL: Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). *J Clin Oncol* 2009; 27(15S):Abst. 4513.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4513>

Protocol(s): S0356

Macdonald JS, Benedetti J, Smalley S, Haller D, Hundahl S, Jessup J, Ajani J, Gunderson L, Goldman B, Martenson J: Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). *J Clin Oncol* 2009; 27(15S):Abst. 4515.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4515>

Protocol(s): INT-0116

Genitourinary Cancer

CALGB

Rini BI, Halabi S, Rosenberg J, Stadler WM, Vaena DA, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ: Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. *J Clin Oncol* 2009; 27(15S):Abst. LBA5019.

<http://meeting.ascopubs.org/cgi/content/abstract/27/18S/LBA5019>

Protocol(s): CALGB-90206

ECOG

Teng j, Liu G, Riley B, Hayney M, Kolesar J: K-ras mutation detected in blood as a predictive factor in patients with recurrent prostate cancer. American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. 5628.

<http://www.abstracksonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={97C23FD6-DAC4-488A-9C9C-695BE6ADEB03}&SKey={87BC5C74-004C-4C3E-8917-1CB3D80150B1}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): E5803

OTHER

Lerner SP, Stein JP, Stadler W, Groshen S, Tuazon E, Skinner DG, Raghavan D, Esrig D, Steinberg GD, Klotz LH, Hall C, Cote RJ: Variability in surgical quality in a randomized clinical trial of adjuvant chemotherapy following radical cystectomy and pelvic lymphadenectomy. American Urological Association, Chicago, Illinois, Apr, 2009.

Protocol(s): SWOG-4B951

Stadler WM, Lerner SP, Groshen S, Stein JP, Skinner DG, Raghavan D, Steinberg GD, Wood D, Klotz LH, Hall C, Cote R: Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ-confined node-negative urothelial bladder cancer (UBC). J Clin Oncol 2009; 27(15S):Abst. 5017.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/5017>

Protocol(s): SWOG-4B951

RTOG

Hamstra D, Bae K, Pilepich M, Hanks G, Grignon D, McGowan D, Roach III M, Lawton C, Lee R, Sandler H: Effect of younger age on metastatic rate and prostate cancer specific death for men treated for prostate cancer with radiation therapy: A secondary analysis of RTOG trials. ASCO Genitourinary Cancers Symposium, Orlando, Florida, Feb, 2009. Abst. 84.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20105

Protocol(s): RTOG-86-10, RTOG-94-13, RTOG-92-02, RTOG-85-31

Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H: Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group (RTOG) prostate clinical trials. J Clin Oncol 2009; 27(15S):Abst. 5123.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/5123>

Protocol(s): RTOG-92-02, RTOG-94-13

SWOG

Glode LM, Tangen CM, Hussain MH, Wood DP, Swanson GP, Quinn DI, Dawson N, Balzer-Haas N, Crawford ED, Thompson IM: Southwest Oncology Group S9921: Prolonged event-free survival in high-risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. J Clin Oncol 2009; 27(15S):Abst. 5009.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/5009>

Protocol(s): S9921

Pinski JK, Goldman B, Dorff T, Mack P, Lara P, van Veldhuizen P, Quinn D, Hussain MH, Thompson IM: SWOG S0354: A phase II trial of CNTO328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pretreated patients (pts) with castration-resistant prostate cancer (CRPC). J Clin Oncol 2009; 27(15S):Abst. 5143.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/5143>

Protocol(s): S0354

Sonpavde G, Goldman BH, Speights V, Lerner SP, Wood DP, Vogelzang NJ, Trump DL, Natale RB, Grossman HB, Crawford Ed: Correlation of quality of pathologic response and surgery with survival for completely resected bladder cancer following neoadjuvant MVAC. ASCO Genitourinary Cancers Symposium, Orlando, Florida, Feb, 2009. Abst. 249.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20039

Protocol(s): INT-0080

Gynecologic Cancer

GOG

Aghajanian C, Sill MW, Darcy K, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie K: A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group (GOG) Study. J Clin Oncol 2009; 27(15S):Abst. 5531.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/5531>

Protocol(s): GOG-0229E

Bialy S, Blessing J, Stehman F, Reardon A, Blaser K, Omura G: Gynecologic Oncology Group (GOG) strategies to improve timeliness of publication with a cooperative group setting. The Society for Clinical Trials, Atlanta, Georgia, May, 2009. Abst. P30.

Protocol(s): Multiple Trials

Chan JK, Tian C, Kesterson J, Monk BJ, Bell JG: Pretreatment CA-125 levels predict for disease recurrence and overall survival in high-risk early stage ovarian cancer patients: a Gynecologic Oncology Group study. Gynecologic Oncology 2009; 112(2):Abst. 36.

<http://sgo.org/content.aspx?id=728>

Protocol(s): GOG-0157

Darcy KM, Tian C, Ambrosone CB, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, DeLoia JA: A Gynecologic Oncology Group study of associations between polymorphisms in ABC transporter genes (ABCB1, ABCC2, and ABCG2) and outcome in advanced stage epithelial ovarian cancer treated with platinum and taxane chemotherapy. J Clin Oncol 2009; 27(15S):Abst. 5567.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/5567>

Protocol(s): GOG-0172

Elgie WE, Killion J, Filiaci G: Web based submission of paper based clinical reports. The Society for Clinical Trials, Atlanta, Georgia, May, 2009. Abst. P10.

Protocol(s): Multiple Trials

Farley JH, Sill M, Walker JL, Schilder RJ, Thigpen JT, Coleman RL, Miller BE: Phase II evaluation of cisplatin plus cetuximab in the treatment of recurrent and persistent cancers of the cervix: A limited access phase II study of the Gynecologic Oncology Group. *J Clin Oncol* 2009; 27(15S):Abst. 5521.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/5521>

Protocol(s): GOG-0076DD

Gaile DP, Shepherd L, Liu S, Darcy K, Brady M, Morrison C: iGenomicViewer, a Gynecologic Oncology Group software library for the creation of highly customizable, portable, interactive, and linked visualizations of high throughput genomic data. *J Clin Oncol* 2009; 27(15S):Abst. e16544.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e16544>

Protocol(s): Multiple Trials

Gardner GJ, Brady M, Bristow RE, Baser RE, Markman M, Spriggs DR, Thaler HT: CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy – a Gynecologic Oncology Group study. *Gynecologic Oncology* 2009; 112(2):Abst. 46.

<http://sco.org/content.aspx?id=728>

Protocol(s): GOG-0114

Gould S: The Gynecologic Oncology Group statistical & Data Center's (GOG#SDC) approach to identifying the transmission of unsecured electronic protected health information (EPHI) using an open source intrusion detection system (IDS). The Society for Clinical Trials, Atlanta, Georgia, May, 2009. Abst. AO6.

Protocol(s): Multiple Trials

Kesterson J, Chan JK, Tian C, Monk BJ, Bell JG: Symptoms of women with high-risk early stage ovarian cancer patients: a Gynecologic Oncology Group study. *Gynecologic Oncology* 2009; 112(2):Abst. 69.

<http://sco.org/content.aspx?id=728>

Protocol(s): GOG-0157

Krivak TC, Tian C, DeLoia JA, Darcy KM, Armstrong D, Gallion H, Davis W, Zhao H, Moysich K, Ambrosone CB: BRCA1/BRCA2 polymorphisms and prognosis in women with optimally-resected stage III epithelial ovarian cancer treated on GOG Protocol 172: A Gynecologic Oncology Group study. *Gynecologic Oncology* 2009; 112(2):Abst. 16.

<http://sco.org/content.aspx?id=728>

Protocol(s): GOG-0172

Leslie KK, Sill MW, Darcy KM, Baron AT, Wilken JA, Godwin AK, Cook L, Schilder RJ, Schilder JM, Maihle NJ: Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. *J Clin Oncol* 2009; 27(15S):Abst. e16542.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e16542>

Protocol(s): GOG-0229C

Leslie KK, Sill MW, Darcy KM, Baron AT, Wilken JA, Godwin AK, Cook L, Schilder RJ, Schilder JM, Maihle NJ: Prognostic value of serum sEGFR and EGFR mutations in a phase II trial of gefitinib (Iressa®, ZD1839) in women with endometrial cancer. American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. LB-134.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={1EF96C8A-B11E-473B-A319-49940F7C54E9}&SKey={8F4E4935-1C08-4601-A578-5171FBE85013}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): GOG-0229C

Levenback CF, Tian C, Coleman RL, Gold MA, Fowler JM, Judson PL: Sentinel node (SN) biopsy in patients with vulvar cancer: A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2009; 27(15S):Abst. 5505.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/5505>

Protocol(s): GOG-0173

Liao S-Y, Darcy K, Randall LM, Tian C, Monk BJ, Burger RA, Fruehauf JP, Barrett RJ, Peters WA, Stock RJ, Stanbridge E: Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 2009; 112(2):Abst. 28.

<http://sco.org/content.aspx?id=728>

Protocol(s): GOG-9911

Miller DS, Blessing JA, Krasner CN, Drake RD, Higgins R, McMeekin DS, Punecky LV: A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND#40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. J Clin Oncol 2009; 27(15S):Abst. e16507.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e16507>

Protocol(s): GOG-01290

Moore KN, Tian C, McMeekin DS, Thigpen JT, Randall ME, Gallion HH: Progression-free interval following first-line chemotherapy in advanced and recurrent endometrial cancer. A Gynecologic Oncology Group ancillary data analysis. Gynecologic Oncology 2009; 112(2):Abst. 65.

<http://sco.org/content.aspx?id=728>

Protocol(s): GOG-0107

Morrison C, Gaile DP, Darcy KM, Liu S, Shepherd L, Cohn D, McMeekin S, Nowak N, Maxwell L: A Gynecologic Oncology Group study of frequent copy number aberrations in African American versus Caucasian women with stage I versus stage IIIC/IV endometrioid endometrial cancer. J Clin Oncol 2009; 27(15S):Abst. e16501.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e16501>

Protocol(s): GOG-0210

Pejovic T, Gaile DP, Darcy KM, Liu S, Shepherd L, Rodgers WH, Kohn E, Mannel R, Birrer MJ, Nowak N: A Gynecologic Oncology Group study of frequent copy number aberrations in DNA repair genes and other genomic regions in stage I serous ovarian cancers. J Clin Oncol 2009; 27(15S):Abst. e16504.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e16504>

Protocol(s): GOG-0175

Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, DeGeest K, Miller BE, Susumu N, Ueland FR: A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study. *J Clin Oncol* 2009; 27(15S):Abst. 5515.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/5515>

Protocol(s): GOG-0232B

Rose PG, Ali S, Whitney CW, Lanciano RM, Stehman FB: Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation therapy and concurrent chemotherapy: a Gynecologic Oncology Group study. *Gynecologic Oncology* 2009; 112(2):Abst. 89.

<http://sco.org/content.aspx?id=728>

Protocol(s): GOG-56

Tiersten A, Sill M, Muggia F, Elera C, Garcia A, Fracasso P, Swensen R, Warshal D, Mannel R: Phase I/feasibility trial of dose-dense carboplatin (C) and paclitaxel (P) in patients (pts) with ovarian cancer: A Gynecologic Oncology Group study. *J Clin Oncol* 2009; 27(15S):Abst. 5544.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/5544>

Protocol(s): GOG-9919

NCIC Clinical Trials Group

Mackay H, Gallinger S, Tsao M, McLachlin CM, Kieser K, Eisenhauer E, Tu D, Oza A: Microsatellite instability and loss of PTEN expression in early versus late-stage endometrial cancer: Results from studies of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). *J Clin Oncol* 2009; 27(15S):Abst. 5534.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/5534>

Protocol(s): NCIC-148, NCIC-160

SWOG

Knight D, Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR, Markman M, Fruehauf JP, Alberts DS: Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: A Southwest Oncology Group Study. *Western Association of Gynecologic Oncologists*, Vancouver, BC, Canada, Jun, 2009.

Protocol(s): S0009

Head and Neck Cancer

ECOG

Argiris A, Ghebremichael M, Gilbert J, Burtness BA, Forastiere AA: A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG). *J Clin Oncol* 2009; 27(15S):Abst. 6011.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6011>

Protocol(s): E1302

Chung CH, Seeley E, Grigorieva J, Yarbough WG, Gilbert J, Murphy BA, Argiris A, Capriolo R, Carbone DP, Erza CE: Mass spectrometry profile as a predictor of overall survival benefit after treatment with epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma. J Clin Oncol 2009; 27(15S):Abst. 6000.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6000>

Protocol(s): E3301

Gilbert J, Argiris A, Haigentz M, Lee J, Burtness BA: Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27(15S):Abst. 6020.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6020>

Protocol(s): E1304

RTOG

Gillison M, Harris J, Westra W, Chung C, Jordan R, Rosenthal D, Nguyen-Tan P, Spanos W, Redmond K, Ang K: Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J Clin Oncol 2009; 27(15S):Abst. 6003.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6003>

Protocol(s): RTOG-0129

Leukemia, Myelodysplasia, and Transplantation

CALGB

Becker H, Marcucci G, Maharry K, Margeson D, Radmacher MD, Whitman SP, Mrózek K, Baer MR, Larson RA, Bloomfield CD: NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML). J Clin Oncol 2009; 27(15S):Abst. 7000.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7000>

Protocol(s): CALGB-10201, CALGB-9720, CALGB-20202

Marcucci G, Maharry K, Whitman SP, Paschka P, Baldus CD, Langer C, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD: Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts). J Clin Oncol 2009; 27(15S):Abst. 7002.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7002>

Protocol(s): CALGB-19808, CALGB-9621, CALGB-20202

Schwind S, Marcucci G, Maharry K, Radmacher MD, Whitman SP, Paschka P, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD: MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML). J Clin Oncol 2009; 27(15S):Abst. 7001.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7001>

Protocol(s): CALGB-19808, CALGB-9621, CALGB-20202

COG

Berg SL, Russell H, Cairo M, Ingle AM, Adamson PC, Blaney SM: Phase I and pharmacokinetic (PK) study of lenalidomide (LEN) in pediatric patients with relapsed/refractory solid tumors or myelodysplastic syndrome (MDS): A Children's Oncology Group Phase I Consortium study. *J Clin Oncol* 2009; 27(15S):Abst. 10023.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10023>

Protocol(s): ADVL0013, ADVL0319

Bhat R, Malinge S, Crispino J: Mutation Analysis of Potential Candidate Genes in Acute Megakaryocytic Leukemia Patients. *Pediatr Blood Cancer* 2009; 52(6):Abst. P162.

<http://aspho.confex.com/aspho/2009/webprogram/Paper2213.html>

Protocol(s): A2971

Gedman AL, Chen Q, Desmoulin SK, Cherian C, Devidas M, Linda SB, Ge Y, Taub JW, Matherly LH: The impact of NOTCH1 on PI3K-AKT signaling and dependence on the PTEN status in T-cell acute lymphoblastic leukemia. American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. 2192.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={47E00B16-F109-4484-81CB-644D18E12AF7}&SKey={5AF7B847-2F56-4878-834E-E274AFDB0672}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): POG-9404, POG-8704

Haugen MS, Toomey DA, Byron P: Webcasting as an Educational Tool for Adult Health Care Providers using a Pediatric-Based Clinical Trial for Adolescents and Young Adults with Acute Lymphoblastic Leukemia. *Oncol Nurs Forum* 2009; 36(3):Abst. 3640.

Protocol(s): AALL0232

Leclerc GJ, Sanderson C, Hunger S, Devidas M, Barredo JC: Non-random translocations alter FPGS and other folate-related genes mRNA expression: TEL-AML1 and E2A-PBX1 fusions specifically down-regulate FPGS transcription in cell lines and primary samples of acute lymphoblastic leukemia. American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. 5687.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={C40451F1-FB46-4B9D-BF87-E77FA8C48ED2}&SKey={46E29416-FE9E-4AC9-B800-CD7E2C0BB741}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): AALL05B1

Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Tasian SK, Schulman BA, Phillips LA, Loh M, Su X, Liu W, Devidas M, Atlas SR, Chen I, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, Willman CL: Frequent JAK mutations in pediatric acute lymphoblastic leukemia with poor outcome: A new therapeutic target in resistant disease. American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. LB-92.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={A61FD20F-FB8D-4900-8F97-D897F19341CE}&SKey={E3374745-1D6F-41AC-AF01-04E20FE15B9A}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): POG-9906

Rollins N, Winick N, Gimi B, Chia J, Wang J: Comparison of Leukemic and Controls Subjects Using Diffusion Tensor Imaging. *Pediatr Blood Cancer* 2009; 52(6):Abst. P150.

<http://aspho.confex.com/aspho/2009/webprogram/Paper2324.html>

Protocol(s): AALL06N1

Schafer ES, Murphy KM, Burns K, McIntyre E, Borowitz M, Hunger S, Wood BL, Carroll AJ, Heerema NA, Harvey RC, Willman CL, Dreyer Z, Devidas M, Brown P: A Custom Quantitative Real Time PCR Minimal Residual Disease (MRD) Assay Predicts Outcome in MLL-Rearranged (MLL-R) Infant ALL: A Children's Oncology Group Study. *Pediatr Blood Cancer* 2009; 52(6):Abst. P302B.

<http://aspho.confex.com/aspho/2009/webprogram/Paper2288.html>

Protocol(s): P9407

Yang JJ, Yang W, Cheng C, Devidas M, Cao X, Campana D, Borowitz M, Willman CL, Bowman W, Reaman GH, Carroll WL, Hunger S, Evans WE, Pui C, Relling MV: Characterization of germline genetic variants underlying racial disparities of childhood leukemia outcome. American Association of Cancer Research (AACR) Cancer Health Disparities, Carefree, Arizona, Feb, 2009. Planery Session 3.

http://www.aacr.org/Uploads/DocumentRepository/2009_conf/CHD09/chd09_final_program_detailed.pdf

Protocol(s): POG-9900, POG-9904, POG-9905, POG-9906

ECOG

Fernandez HF, Sun Z, Bennett JM, Paietta EM, Litzow MR, Rowe JM, Luger SM, Lazarus HM, Tallman MS: A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900. *J Clin Oncol* 2009; 27(15S):Abst. 7003.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7003>

Protocol(s): E1900

Lymphoma and Plasma Cell Disorders

COG

Abromowitch M, Termuhlen A, Lynch J, Chang M, Perkins S, Gross TG, Weinstein H, Finlay J: High-Dose Methotrexate and Early Intensification of Therapy Do Not Improve 3 Year EFS in Children and Adolescents with Disseminated Lymphoblastic Lymphoma. Results of the Randomized Arms of COG A5971. *Hematology Meetings Reports* 2009; 3(5):Abst. 56.

Protocol(s): A5971

Burke MJ, Dayton V: Treatment of a CNS Relapse while on Therapy for Burkitt Lymphoma. *Hematology Meetings Reports* 2009; 3(5):Abst. 97.

Protocol(s): ANHL01P1

Coustan-Smith E, Sandlund JT, Perkins S, Chen HR, Chang M, Abromowitch M, Campana D: Minimal Disseminated Disease In Childhood T-Cell Lymphoblastic Lymphoma: A Report From The Children's Oncology Group. *Hematology Meetings Reports* 2009; 3(5):Abst. 17.

Protocol(s): A5971

Goldman SC, Lynch J, Harrison L, Cairo M: Effective and Safe Acute Tumor Lysis Syndrome (ATLS) Prophylaxis with Rasburicase and Non-Alkaline Hydration in Children and Adolescents with Advanced Stage III/IV Intermediate Risk B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report. *Pediatr Blood Cancer* 2009; 52(6):Abst. P145.

<http://aspho.confex.com/aspho/2009/webprogram/Paper2128.html>

Protocol(s): ANHL01P1

Goldman SC, Lynch J, Harrison L, Cairo M: Effective and Safe Acute Tumor Lysis Syndrome (ATLS) Prophylaxis and Treatment (P+T) with Rasburicase (R) and Non-Alkaline Hydration in Children and Adolescents (C+A) with High –Risk FAB Group C Mature B- Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report. Hematology Meetings Reports 2009; 3(5):Abst. 146.
Protocol(s): ANHL01P1

Goldman SC, Lynch J, Harrison L, VandeVen C, Gross TG, Shiramizu B, Sanger W, Perkins S, Cairo M: Safety and Kinetics of Rituximab (R) following Chemoimmunotherapy (Rituximab + FAB Chemotherapy) in Children and Adolescents with Mature B-cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report. Hematology Meetings Reports 2009; 3(5):Abst. 138.
Protocol(s): ANHL01P1

Goldman SC, Lynch J, Harrison L, VandeVen C, Gross TG, Shiramizu B, Sanger W, Perkins S, Cairo M: Rituximab combined with FAB Group B4 therapy in children and adolescents with stage III/IV mature BNHL : A Children's Oncology Group Report. Hematology Meetings Reports 2009; 3(5):Abst. 141.
Protocol(s): ANHL01P1

Gross TG, Orjuela MA, Hayashi RJ, Cairo M, Lynch J: Preliminary results of low-dose chemotherapy and rituximab for pediatric patients with EBV(+), CD20(+) post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation (SOT): A Children's Oncology Group Phase II study. International Pediatric Transplant Association, Istanbul, Turkey, Apr, 2009. Abst. LB 15.
<http://www.iptaonline.org/5thcongress/>
Protocol(s): ANHL0221

Gross TG, Orjuela MA, Hayashi RJ, Park J, Perkins S, Cairo M, Lynch J: Pediatric, Refractory Post-Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT): a Children's Oncology Group Phase II Study. Hematology Meetings Reports 2009; 3(5):Abst. 126.
Protocol(s): ANHL0221

Kraveka JM, Weitzman S, Smith LM, Lynch J, Chang M, Kinney MC, Perkins S, Laver J, Gross TG, Weinstein H: Advanced-Stage Anaplastic Large-Cell Lymphoma in Children and Adolescents: Results of ANHL0131, a Randomized Phase III Trial with Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation with a Regimen Including Vinblastine: A Report from the Children's Oncology Group. Hematology Meetings Reports 2009; 3(5):Abst. 68.
Protocol(s): ANHL0131

Patel JL, Lones MA, Abromowitch M, Cairo M, Perkins S: Precursor T-Lymphoblastic Lymphoma in Children and Adolescents: An Immunophenotypic Analysis of a Large Cohort (N=186): a Children's Oncology Group Report. Hematology Meetings Reports 2009; 3(5):Abst. 61.
Protocol(s): A5971

Termuhlen A, Lynch J, Perkins S, Gross TG, Weinstein H, Finlay J, Chang M, Abromowitch M: Outcome of Newly Diagnosed Children and Adolescents with Localized Lymphoblastic Lymphoma Treated on COG A5971: A Report from the Children's Oncology Group. Hematology Meetings Reports 2009; 3(5):Abst. 59.
Protocol(s): A5971

NCCTG

Micallef IN, Maurer MJ, Nikcevich DA, Cannon MW, Schaefer EW, Moore DF, Kurtin P, Witzig TE: Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. *J Clin Oncol* 2009; 27(15S):Abst. 8508.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8508>

Protocol(s): N0489

SWOG

Barlogie B, Attal M, Crowley J, Harousseau J: Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): Update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials. *J Clin Oncol* 2009; 27(15S):Abst. 8519.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8519>

Protocol(s): INT-0141

Crowley J, Bolejack V, Robert K, Anderson K, Barlogie B: Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): Examining whether different variables govern different time segments of survival. *J Clin Oncol* 2009; 27(15S):Abst. 8599.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8599>

Protocol(s): INT-0141

Dhodapkar MV, Bolejack V, Shaughnessy J, Matthews P, Pickering R, Qu P, Hoering A, Crowley J, Barlogie B: Role of T-cell immunity to embryonal stem (ES) cell antigen SOX2 in the progression of myeloma. *J Clin Oncol* 2009; 27(15S):Abst. 8522.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8522>

Protocol(s): S0120

Srkalovic G, Hussein M, Bolejack V, Hoering A, Zonder J, Barlogie B: A phase II trial of sorafenib in patients with relapsing and resistant multiple myeloma (MM) previously treated with bortezomib (S0434). *J Clin Oncol* 2009; 27(15S):Abst. E19517.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e19517>

Protocol(s): S0434

Lung Cancer

ACOSOG

Scott W, Allen M, Meyers B, Decker P, Putnam JB: Perioperative Outcomes of Video-Assisted (VATS) Resection for Lung Cancer Compared to Open Thoracotomy: An Analysis of Data from the American College of Surgeons Oncology Group (ACOSOG) Z0030 Clinical Trial. Western Thoracic Surgical Association, Banff, AB Canada, Jun, 2009. Abst. 2.

<http://www.westernthoracic.org/Abstracts/2009/2.html>

Protocol(s): ACOSOG-Z0030

CALGB

Govindan R, Bogart J, Wang X, Hodgson L, Kratzke R, Vokes EE: Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. *J Clin Oncol* 2009; 27(15S):Abst. 7505.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7505>

Protocol(s): CALGB-30407

Kohman L, Watson D, Herndon J, Eves N, Haithcock B, Loewen G, Jones L: CALGB 140803—Association between cardiorespiratory fitness and overall survival in operable lung cancer patients: Ancillary analysis of protocol 9238. *J Clin Oncol* 2009; 27(15S):Abst. 7518.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7518>

Protocol(s): CALGB-9238

Stinchcombe TE, Hodgson L, Herndon JE, Kelley MJ, Cicchetti M, Ramnath N, Niell HB, Atkins JN, Green MR, Vokes EE: Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801. *J Clin Oncol* 2009; 27(15S):Abst. 7535.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7535>

Protocol(s): CALGB-39801

ECOG

Amann S, Lee J, Roder H, Brahmer JR, Schiller JH, Carbone DP: Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer. *J Clin Oncol* 2009; 27(15S):Abst. 8089.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8089>

Protocol(s): E3503

Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH: Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599. *J Clin Oncol* 2009; 27(15S):Abst. 8042.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8042>

Protocol(s): E4599

Schiller JH, Dahlberg SE, Mehta MP, Johnson DH: A phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide in patients with stage III non-small cell carcinoma of the lung (NSCLC): E3598. *J Clin Oncol* 2009; 27(15S):Abst. 7503.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7503>

Protocol(s): EST-3589

Zhang W, Dahlberg SE, Yang D, Sandler AB, Brahmer JR, Schiller JH, Carbone DP, Johnson DH, Lenz H: Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599. *J Clin Oncol* 2009; 27(15S):Abst. 8032.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8032>

Protocol(s): E4599

NCCTG

Foster NR, Qi Y, Krook JE, Kugler JW, Kuross SA, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ: Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. *J Clin Oncol* 2009; 27(15S):Abst. 8085.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8085>

Protocol(s): Multiple Trials

Schild S, Graham D, Hillman S, Vora S, Yolanda G, Molina J, Shahidi H, Kugler J, Adjei A: Survival of patients (pts) treated with high-dose radiotherapy (RT) and concurrent chemotherapy for unresectable non-small cell lung cancer (NSCLC). *J Clin Oncol* 2009; 27(15S):Abst. 7544.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7544>

Protocol(s): N0028

Zhao X, Sloan J, Yang P, Sargent D, Wampfler J, Shao Y: Baseline quality of life as a prognostic factor for overall survival in lung cancer patients. *J Clin Oncol* 2009; 27(15S):Abst. e19031.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e19031>

Protocol(s): Multiple Trials

NCIC Clinical Trials Group

Twumasi-Ankrah P, Ding K, Seymour L, Shepherd F: Identifying non-responders of vinorelbine plus cisplatin in adjuvant chemotherapy in completely resected non-small cell lung cancer. The Society for Clinical Trials, Atlanta, Georgia, May, 2009. Abst. 93.

Protocol(s): JBR10

Vincent MD, Butts C, Seymour L, Ding K, Graham B, Twumasi-Ankrah P, Gandara D, Schiller J, Green M, Shepherd F: Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC). *J Clin Oncol* 2009; 27(15S):Abst. 7501.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7501>

Protocol(s): JBR10

RTOG

Gore E, Bae K, Wong S, Bonner J, Sun A, Schild S, Gaspar L, Bogart J, Werner-Wasik M, Choy H: A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214. *J Clin Oncol* 2009; 27(15S):Abst. 7506.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7506>

Protocol(s): RTOG-0214

Komaki R, Paulus R, Ettinger D, Videtic G, Bradley J, Glisson B, Choy H: A phase II study of accelerated high-dose thoracic radiation therapy (AHTRT) with concurrent chemotherapy for limited small cell lung cancer: RTOG 0239. *J Clin Oncol* 2009; 27(15S):Abst. 7527.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7527>

Protocol(s): RTOG-0239

SWOG

Franklin WA, Gandara DR, Kim ES, Herbst RS, Moon J, Redman MW, Olsen C, Hirsch FR, Mack P, Kelly K: SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(15S):Abst. 11076.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/11076>

Protocol(s): S0342, S0536

Gandara D, Kim ES, Herbst RS, Moon J, Redman MW, Dakhil SR, Hirsch F, Mack PC, Franklin W, Kelly K: S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. J Clin Oncol 2009; 27(15S):Abst. 8015.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8015>

Protocol(s): S0536

Garland LL, Chansky K, Wozniak A, Tsao A, Gadgeel S, Vershraegen C, Da Silva M, Redman M, Gandara D: SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. J Clin Oncol 2009; 27(15S):Abst. 7511.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7511>

Protocol(s): S0509

Lara P, Chansky K, Shibata T, Fukuda H, Tamura T, Saijo N, Redman M, Lenz HJ, Natale R, Gandara DR: Cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer (E-SCLC): Final "common arm": Comparative outcomes analysis of JCOG 9511 and SWOG 0124. J Clin Oncol 2009; 27(15S):Abst. 8027.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8027>

Protocol(s): S0124

Mack PC, Holland WS, Redman M, Lara PN, Snyder LJ, Hirsch FR, Franklin WA, Kim ES, Herbst RS, Gandara DR: KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. J Clin Oncol 2009; 27(15S):Abst. 8022.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8022>

Protocol(s): S0536, S0342

Melanoma/Skin Cancers

NCCTG

Markovic SN, Suman VJ, Kottschade LA, Amatruda T, McWilliams RR, Dakhil SR, Nikcevich DA, Morton RF, Fitch TR, Jaslowski AJ: A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: Final data from N057E. J Clin Oncol 2009; 27(15S):Abst. 9055.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/9055>

Protocol(s): N057E

SWOG

Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Balzer-Haas NS, Merl SA, DeConti RC, Thompson JA, Flaherty LE, Sondak VK: A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group Study (S0331). *J Clin Oncol* 2009; 27(15S):Abst. 9056.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/9056>

Protocol(s): S0331

Sarcoma/Bone and Soft Tissue Cancers

COG

van Doorninck J, Ji L, Okamoto C, Cooper A, Wing M, Womer R, Krailo M, Ladanyi M, Shimada H, Triche TJ, Sposto R, Lawlor ER: Ewing family tumors that do not over-express BMI-1 are a distinct subclass that arise from alternate mechanisms of molecular transformation. *American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. 2185.*

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={C024960F-6952-431C-86A7-2D311C0174D9}&SKey={5AF7B847-2F56-4878-834E-E274AFDB0672}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): AEWS0031

RTOG

Howell D, James J, Hartsell W, Suntharalingam M, Machtay M, Suh J, Demas W, Sandler H, Kachnic L, Berk L: Randomized trial of short-course versus long-course radiotherapy for palliation of painful vertebral bone metastases: A retrospective analysis of RTOG 97–14. *J Clin Oncol* 2009; 27(15S):Abst. 9521.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/9521>

Protocol(s): RTOG-97-14

SWOG

Schuetze S, Rutkowski P, Van Glabbeke MM, Rankin C, Rubin BP, Lazar A, Debiec-Rychter M, Gelderblom H, Hohenberger P, van Oosterom AT: Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP). *J Clin Oncol* 2009; 27(15S):Abst. 10520.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10520>

Protocol(s): S0345

Other Cancer

COG

Bagatell R, Wagner LM, Cohn SL, Maris JM, Reynolds CP, Stewart CF, Voss SD, Gelfand M, Kretschmar CS, London WB: Irinotecan plus temozolomide in children with recurrent or refractory neuroblastoma: A phase II Children's Oncology Group study. *J Clin Oncol* 2009; 27(15S):Abst. 10011.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10011>

Protocol(s): ANBL0421

Escoto H, London W, McGrady PW, Kravaka JM: Association of High Ceramide Levels with Unfavorable Neuroblastoma Risk Factors: A Report from the Children's Oncology Group. *Pediatr Blood Cancer* 2009; 52(6):Abst. P207.

<http://aspho.confex.com/aspho/2009/webprogram/Paper2142.html>

Protocol(s): ANBL00B1

Escoto H, London WB, McGrady P, Kravaka JM: Association of high ceramide levels with unfavorable neuroblastoma risk factors: A report from the children's oncology group. *American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. 4049.*

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={CB95D8D1-CA65-48E0-9A5D-48528AA3FE94}&SKey={FA937F68-7D59-4834-BE38-E0C764AEE4B5}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): ANBL00B1

Gumy-Pause F, Ozsahin H, Khoshbeen-Boudal M, Pardo B, Betts D, Maillet P, Sappino A: ATM gene analysis in neuroblastoma: A report from the COG. *J Clin Oncol* 2009; 27(15S):Abst. 10058.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10058>

Protocol(s): ANBL07B1

Johnson KJ, Ross JA, Poynter JN, Linabery AM, Robison LL, Shu XO: Pediatric germ cell tumors and congenital abnormalities: A Children's Oncology Group Study. *American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. 990.*

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={9B48CC5A-95A7-4E05-8AC1-E994104A5235}&SKey={30B8D593-71B0-4C9C-A140-C8335DA2A975}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): AE22

Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Fox FE, Voss S, Adamson PC, Blaney SM: A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study. *J Clin Oncol* 2009; 27(15S):Abst. 10013.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10013>

Protocol(s): ADVL0712

Malogolowkin MH, Krailo M, Frazier LA, Olson TA: Study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high-risk germ cell tumors: A Children's Oncology Group report. *J Clin Oncol* 2009; 27(15S):Abst. 10035.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10035>

Protocol(s): INT-0097

McCarten KM, Rosen NS, Friedman D, Schwartz C, Voss SD, FitzGerald TJ: Feasibility of Real Time Diagnostic Imaging Central Review in Multicenter Cancer Trials. *Am J Roentgenol* 2009; 192(5S):Abst. 76.

<http://www.ajronline.org/>

Protocol(s): AHOD0031

Oakley BE, Docherty S, Burns DS, Roll LJ, Hendricks-Ferguson VL, Stegenga K, Haase JE: Planning, Implementing, and Monitoring Strategies for Recruitment of Adolescents/Young Adults into a Randomized Clinical Trial. *Oncol Nurs Forum* 2009; 36(1):Abst. AM.

<http://www.ons.org/meetings/research09/>

Protocol(s): ANUR0631

Phillips-Salimi C, Carter Kooken W, Haase JE: The Connectedness-Vigilance Advantage: Untapped Resources for Cancer Care. *Oncol Nurs Forum* 2009; 36(1):Abst. DJ.

<http://www.ons.org/meetings/research09/>

Protocol(s): ANUR0631

Poynter JN, Radzom AH, Spector LG, Puumala S, Robison LL, Chen Z, Ross JA, Shu XO: Family history of cancer and malignant germ cell tumors in children: A report from the Children's Oncology Group. American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. 991.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={43DD09B9-D1B3-435B-BF5B-686505269732}&SKey={30B8D593-71B0-4C9C-A140-C8335DA2A975}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): AE22

Robb SL, Burns DS, Haase JE: Researchers and Clinicians Engaged in SMART Quality Assurance Monitoring. American Psychosocial Oncology, Charlotte, North Carolina, Feb, 2009. Abst. P2-24.

<http://apos.conference-services.net/reports/template/onetextabstract.xml?xsl=template/onetextabstract.xsl&conferenceID=1446&abstractID=267080>

Protocol(s): ANUR0631

Sencer S, Zhou T, Oberbaum M, Freedman L, McLean TW, Sahdev I, Ives JA, Jonas WB: The Efficacy of the Homeopathic Agent Traumeel S® in the Prevention and Treatment of Mucositis in Children Undergoing Stem Cell Transplantation. *Pediatr Blood Cancer* 2009; 52(6):Abst. P104.

<http://aspho.confex.com/aspho/2009/webprogram/Paper2380.html>

Protocol(s): ACCL0331

Stegenga K, Docherty S, Phillips-Salimi C, Donovan M, Hendricks-Ferguson VL, Barnes YJ, Haase JE: The SMART Approach: An Innovative Method to Multi-site Qualitative Data Collection and Analysis. *Oncol Nurs Forum* 2009; 36(1):Abst. CK.

<http://www.ons.org/meetings/research09/>

Protocol(s): ANUR0631

Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD, Ingle AM, Blaney SM, Adamson PC: Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium study. *J Clin Oncol* 2009; 27(15S):Abst. 10017.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10017>

Protocol(s): ADVL0414

Widemann BC, Fox E, Adamson PC, Baruchel S, Kim A, Ingle AM, Bender JG, Stempak D, Balis FM, Blaney SM: Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial. *J Clin Oncol* 2009; 27(15S):Abst. 10012.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10012>

Protocol(s): ADVL0413

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman S, Chen HX, Matthay KK, Cohn SL, Maris JM, Sondel P: A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032. *J Clin Oncol* 2009; 27(15S):Abst. 10067z.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=35748

Protocol(s): ANBL0032

ECOG

Fisch MJ, Lee J, Manola J, Wagner LI, Chang VT, Gilman PB, Lear KA, Baez-Diaz L, Cleeland C: Survey of disease and treatment-related symptoms in outpatients with invasive cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study). *J Clin Oncol* 2009; 27(15S):Abst. 9619.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/9619>

Protocol(s): E2Z02

Jenab-Wolcott J, Catalano P, Fillingham BD, Ferriere MR, O'Dwyer PJ, Giantonio BJ: Voluntary submission of biological specimens from cancer clinical trials: An update of the Eastern Cooperative Oncology Group experience. *J Clin Oncol* 2009; 27(15S):Abst. 6597.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6597>

Protocol(s): Multiple Trials

NCCTG

Barton DL, Wos E, Qin R, Mattar B, Green N, Lanier K, Bearden J, Kugler J, Rowland K, Loprinzi C: A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA. *J Clin Oncol* 2009; 27(15S):Abst. 9531.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/9531>

Protocol(s): N06CA

Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Windschitl HE, Zhao X, Loprinzi CL: Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial. *J Clin Oncol* 2009; 27(15S):Abst. 4025.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4025>

Protocol(s): N04C7

Kottschade LA, Sloan JA, Mazureczak MA, Johnson DB, Murphy B, Rowland KM, Smith DA, Berg A, Stella PJ, Loprinzi CL: The use of vitamin E for prevention of chemotherapy-induced peripheral neuropathy: A phase III double-blind, placebo controlled study—N05C3. *J Clin Oncol* 2009; 27(15S):Abst. 9532.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/9532>

Protocol(s): N05C3

Liu H, Sloan JA, Sargent DJ, Satele DV, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Buckner JC: Assessing simple measures of patient-reported (PR) fatigue for oncology clinical trials: A pooled analysis of 3,915 patients. *J Clin Oncol* 2009; 27(15S):Abst. 9563.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/9563>

Protocol(s): Multiple Trials

Loprinzi CL, Qin R, Stella PJ, Rowland KM, Graham DL, Erwin N, Dakhil SR, Jurgens DJ, Burger KN: Pregabalin for hot flashes in women: NCCTG trial N07C1. *J Clin Oncol* 2009; 27(15S):Abst. 9513.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/9513>

Protocol(s): N07C1

Sloan JA, Liu H, Sargent DJ, Satele D, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Loprinzi CL, Buckner JC: A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. *J Clin Oncol* 2009; 27(15S):Abst. 9599.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/9599>

Protocol(s): Multiple Trials

Tang H, Foster NR, Grothey A, Ansell SM, Sargent DJ: Excessive false-positive errors in single-arm phase II trials: A simulation-based analysis. *J Clin Oncol* 2009; 27(15S):Abst. 6512.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6512>

Protocol(s): Multiple Trials

Wolf SL, Qin R, Barton DL, Sloan JA, Liu H, Aaronson NK, Satele DV, Green NB, Mattar BI, Loprinzi CL: Relationship of sensory symptoms and motor function in patients with chemotherapy-induced peripheral neuropathy (CIPN) utilizing the EORTC QLQ CIPN20: NCCTG study N06CA. *J Clin Oncol* 2009; 27(15S):Abst. 9587.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/9587>

Protocol(s): N06CA

NCIC Clinical Trials Group

Oza AM, Kollmannsberger C, Hirte H, Welch S, Siu L, Mazurka J, Sederias J, Doyle LA, Eisenhauer E: Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179. *J Clin Oncol* 2009; 27(15S):Abst. 3558.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/3558>

Protocol(s): NCIC-179

NSABP

Cook ED, Wilson JW, Gibson RV: Minority retention similar to that of whites in NSABP cancer treatment trials. American Association of Cancer Research (AACR) Cancer Health Disparities, Carefree, Arizona, Feb, 2009. Poster Session B12.

http://www.aacr.org/Uploads/DocumentRepository/2009_conf/CHD09/chd09_final_program_detailed.pdf

Protocol(s): NSABP-B-30, NSABP-B-31, NSABP-B-32, NSABP-B-34, NSABP-B-35, NSABP-B-36, NSABP-B-38, NSABP-B-39, NSABP-C-08, NSABP-R-04

Schroen AT, Petroni GR, Wang H, Djulbegovic B, Slingluff CL, Jr, Wang XF, Gray R, Sargent DJ, Cronin W, Benedetti J: Challenges to accrual predictions to phase III cancer clinical trials: A survey of study chairs and lead statisticians of 248 NCI-sponsored trials. *J Clin Oncol* 2009; 27(15S):Abst. 6562.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6562>

Protocol(s): NSABP-B-18, NSABP-B-20, NSABP-B-21, NSABP-B-22, NSABP-B-23, NSABP-B-24, NSABP-B-25, NSABP-B-27, NSABP-B-28, NSABP-B-29, NSABP-B-30, NSABP-B-32, NSABP-B-33, NSABP-B-34, NSABP-C-05, NSABP-C-06, NSABP-C-07, NSABP-R-03, Multiple Trials (NCCTG and OTHER)

SWOG

Hoban CJ, Hoering A, Synold TW, Chung V, Gandara DR, Schott AF, Kingsbury L, Lew D, LoRusso PM, Gadgeel SM: Phase I evaluation of lapatinib and everolimus in patients with advanced malignancies: Southwest Oncology Group trial S0528. *J Clin Oncol* 2009; 27(15S):Abst. 3553.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/3553>

Protocol(s): S0528

NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators

Bleyer A, Friedman S, Finnegan S, Montello M, Budd T, Anderson B, Trimble EL: Association of adolescent and young adult cancer treatment trial activity with a national mortality reduction benefit in the United States. *J Clin Oncol* 2009; 27(15S):Abst. 6605.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6605>

Carol H, Lock RB, Houghton PJ, Morton CL, Maris JM, Courtright J, Kolb EA, Gorlick R, Friedman HS, Keir ST, Kang M, Reynolds CP, Smith MA: Pediatric preclinical testing program (PPTP) evaluation of the Akt inhibitor GSK690693. American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. 3193.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={E136F546-F547-4CCD-9D89-BBADC929F95C}&SKey={5F41110E-C96A-49BA-BEB4-33F45759FC53}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Cheng S, Dietrich M, Finnigan S, Sandler A, Crites J, Ferranti L, Wu A, Dilts D: A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. *J Clin Oncol* 2009; 27(15S):Abst. CRA6509.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/CRA6509>

Grubbs SS, Gonzalez M, Krasna M, Siegel R, Bryant D, Tschetter L, Hayenga L, Duggan B, St. Germaine D, Denicoff A: Tracking clinical trial accrual strategies and barriers via a Web-based screening tool. *J Clin Oncol* 2009; 27(15S):Abst. 6586.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6586>

Kolb EA, Gorlick R, Houghton PJ, Morton CL, Maris JM, Courtright J, Carol H, Lock RB, Friedman HS, Keir ST, Kang M, Reynolds CP, Smith MA: Pediatric Preclinical Testing Program (PPTP) evaluation of the multi-targeted kinase inhibitor Sorafenib. American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. 3196.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={B1EF59CC-4F6F-4E1A-964F-F2BC2524A94F}&SKey={5F41110E-C96A-49BA-BEB4-33F45759FC53}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Carol H, Lock RB, Friedman HS, Keir ST, Kang M, Reynolds CP, Smith MA: Pediatric Preclinical Testing Program (PPTP) evaluation of the novel polyamine analogue PG11047. American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. 3194.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={AA2E80C5-933D-4894-8D30-E5A027021AC5}&SKey={5F41110E-C96A-49BA-BEB4-33F45759FC53}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Morton CL, Houghton PJ, Maris JM, Courtright J, Kolb EA, Gorlick R, Carol H, Lock RB, Friedman HS, Keir ST, Kang M, Reynolds CP, Smith MA: Pediatric Preclinical Testing Program (PPTP) evaluation of PR-104. American Association of Cancer Research (AACR), Denver, Colorado, Apr, 2009. Abst. 3195.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={258FC492-40E8-43F2-83E9-68241D9E5CE3}&SKey={5F41110E-C96A-49BA-BEB4-33F45759FC53}&MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

O'Mara AM, Denicoff AM, Reeve B, Burns R, Trimble T: A comparison of patient-reported outcomes (PROs) in National Cancer Institute-sponsored cancer treatment trials conducted during two time periods: 1999–2003 and 2003–2008. J Clin Oncol 2009; 27(15S):Abst. 6618.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/6618>

Smith MA, Morton CL, Carol H, Gorlick RG, Kang MH, Keir ST, Kolb EA, Lock RB, Maris JM, Houghton PJ: Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A. J Clin Oncol 2009; 27(15S):Abst 10015.

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/10015>

Significant Publications of Interest

RECIST Version 1.1

Eisenhauer E, Jaap Verweij J, Therasse P: Response assessment in solid tumours (RECIST): Version 1.1 and supporting papers. European J of Cancer 2009; 45(2): Pgs 225-310.

http://www.sciencedirect.com/science?_ob=PublicationURL&_tockey=%23TOC%235024%232009%23999549997%23790193%23FLA%23&_cdi=5024&_pubType=J&view=c&_auth=v&_acct=C000000150&_version=1&_urlVersion=0&_userid=10843&md5=b36f8d2630e7c9041fc4afd2928eb4b2

Jaap Verweij J, Therasse P, Eisenhauer E: Cancer clinical trial outcomes: Any progress in tumour-size assessment? European J of Cancer 2009; 45(2): Pgs 225-227.

<http://www.sciencedirect.com/science/article/B6T68-4V3RCH5-5/2/5bb0c9c9abb69405567a431c4d8f3a9c>

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European J of Cancer 2009; 45(2): Pgs 228-247.

<http://www.sciencedirect.com/science/article/B6T68-4V7D0M4-2/2/64aaa609c60a9f0b4f66a88205c97e27>

Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, Eisenhauer E, Verweij J, Therasse P: Individual patient data analysis to assess modifications to the RECIST criteria. European J of Cancer 2009; 45(2): Pgs 248-260.

<http://www.sciencedirect.com/science/article/B6T68-4V5F016-2/2/74bb15f78a51d3e1ba184122fdd507da>

Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, Gwyther S, Eisenhauer EA: Evaluation of lymph nodes with RECIST 1.1. European J of Cancer 2009; 45(2): Pgs 261-267.

<http://www.sciencedirect.com/science/article/B6T68-4V5DWRH-4/2/80eb2daf283454053d85acf3ea11a329>

Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J: Lessons learned from independent central review. European J of Cancer 2009; 45(2): Pgs 268-274.

<http://www.sciencedirect.com/science/article/B6T68-4V7CYW6-2/2/fba10c3e7459e2fdfd1cf941b0d056b8>

Ratain MJ, Sargent DJ: Optimising the design of phase II oncology trials: The importance of randomisation. *European J of Cancer* 2009; 45(2): Pgs 275-280.

<http://www.sciencedirect.com/science/article/B6T68-4V357P9-1/2/da429267ab5d8692ae21d452a841cf1e>

Dancey JE, Dodd LE, Ford R, Kaplan R, Mooney M, Rubinstein L, Schwartz LH, Shankar L, Therasse P: Recommendations for the assessment of progression in randomised cancer treatment trials. *European J of Cancer* 2009; 45(2): Pgs 281-289.

<http://www.sciencedirect.com/science/article/B6T68-4V7D0M4-1/2/c29d93425efc6e97b99190d01b280d58>

Sargent DJ, Rubinstein L, Schwartz L, Dancey JE, Gatsonis C, Dodd LE, Shankar LK: Validation of novel imaging methodologies for use as cancer clinical trial end-points. *European J of Cancer* 2009; 45(2): Pgs 290-299.

<http://www.sciencedirect.com/science/article/B6T68-4V5DWRH-6/2/9dc042004c186e6559630610cdcb868a>

Moskowitz CS, Jia X, Schwartz LH, Gonen M: A simulation study to evaluate the impact of the number of lesions measured on response assessment. *European J of Cancer* 2009; 45(2): Pgs 300-310.

<http://www.sciencedirect.com/science/article/B6T68-4V5F016-4/2/aff418088e988571b80609ccd8e73cfe>

Disclaimer: *References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References will appear under only one disease heading chosen as the primary disease but will appear under as many Cooperative Group subheadings as is applicable. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may also be included upon agreement and provided the required information is available. Links to online abstracts have been provided where they were available at the time of publication but there is no guarantee that these links will remain active.*